GE and National Cancer Institute team up for nanoparticle imaging agents
This article was originally published in Clinica
GE Healthcare has signed a two-year agreement with the US National Cancer Institute to develop nanoparticle-based imaging agents for the diagnosis and treatment of cancer and heart disease. The institute's Nanotechnology Characterization Laboratory will evaluate the safety and feasibility of GE's nanoparticle diagnostic imaging agents. The Chalfont St Giles, UK firm hopes they could lead to earlier detection of cancers and cardiac diseases, and monitor the effectiveness of treatments, by allowing doctors to see and target disease with higher resolution and sensitivity.